International Consensus Recommendations for the Treatment of Pediatric NMDAR Antibody Encephalitis

Margherita Nosadini, MD, PhD, Terrence Thomas, MD, Michael Eyre, MD, Banu Anlar, MD, Thais Armanag, MD, PhD, Susanne M. Benseler, MD, Tania Cellucci, MD, FRCP, MScCH, Kumaran Deiva, MD, William Gallentine, DO, Grace Gombolay, MD, Mark P. Gorman, MD, Yael Hacohen, MD, Yuwu Jiang, MD, Byung Chan Lim, MD, Eyal Muscal, MD, MS, Alvin Ndondo, MD, Rinze Neuteboom, MD, PhD, Kevin Rostasy, MD, Hiroshi Sakuma, MD, Suvasini Sharma, MD, Silvia Noemi Tenembaum, MD, Heather Ann Van Mater, MD, Elizabeth Wells, MD, Ronny Wickstrom, MD, PhD, Anushka K. Yeshokumar, MD, Sarosh R. Irani, MD, PhD, Josep Dalmau, MD, PhD, Ming Lim, MD, PhD, and Russell C. Dale, MD, PhD

Neurrol Neuroimmunol Neuroinflamm 9:8:e1052. doi:10.1212/NXI.0000000000001052

Abstract

Objective

To create an international consensus treatment recommendation for pediatric NMDA receptor antibody encephalitis (NMDARE).

Methods

After selection of a panel of 27 experts with representation from all continents, a 2-step Delphi method was adopted to develop consensus on relevant treatment regimens and statements, along with key definitions in pediatric NMDARE (disease severity, failure to improve, and relapse). Finally, an online face-to-face meeting was held to reach consensus (defined as ≥75% agreement).

Results

Corticosteroids are recommended in all children with NMDARE (pulsed IV preferred), with additional IV immunoglobulin or plasma exchange in severe patients. Prolonged first-line immunotherapy can be offered for up to 3–12 months (oral corticosteroids or monthly IV corticosteroids/immunoglobulin), dependent on disease severity. Second-line treatments are recommended for cases refractory to first-line therapies (rituximab preferred over...
NMDA receptor antibody encephalitis (NMDARE) is one of the most common autoimmune encephalitides, characterized by a recognizable constellation of neurologic and psychiatric features alongside positive NMDAR antibodies.¹,² NMDARE mostly affects children and young adults, particularly females. It may be very severe in the acute phase with a mortality of about 5%, relapses occur in about 15% of patients, and the final physician-assessed functional outcome is generally favorable, although neuropsychological and psychiatric sequelae are relatively common.²,³

The use of immunotherapies has been shown to improve outcomes,²,⁴,⁶ especially with early administration.²,⁴,⁶,⁷ In addition, immunotherapies reduce the risk of relapses.²,⁸,⁹ However, several aspects of treatment remain incompletely clarified, and treatment strategies are still heterogeneous, especially with regard to second-line and long-term immunotherapies.¹⁰,¹¹ Indeed, although a number of reviews have been published,¹²⁻¹⁸ no randomized controlled trials or consensus guidelines for the treatment of NMDARE are available.

With support from the Autoimmune Encephalitis Alliance, we aimed to create a consensus recommendation for the treatment of pediatric NMDARE, which was pragmatic and relevant to a global community and could serve as a practical decision support tool for the clinician confronted with this rare and challenging condition. Notably, the present document is intended as a recommendation guideline rather than absolute rules, given the limited evidence supporting most treatment statements. Although this document is focused on immunotherapy and to some extent symptomatic management, there are multiple outstanding issues in the management of pediatric NMDARE, such as education around the diagnosis and rehabilitation of patients after the acute phase, which are beyond the scope of this current article.

Conclusion
These international consensus recommendations for the management of pediatric NMDARE aim to standardize the treatment and provide practical guidance for clinicians, rather than absolute rules. A similar recommendation could be applicable to adult patients.

Methods
Establishment of a Consensus Expert Panel
A steering committee (R.C.D., M.L., T.T., M.N., and M.E.) carefully selected a panel of 27 experts with representation from all continents (later referred to as “the Panel”), and based on the individual: (1) being a specialist (usually pediatric neurologist or rheumatologist) with clinical and/or research expertise in pediatric NMDARE; these experts were identified as lead clinical researchers in the field, based on the systematic review conducted before the consensus recommendations project (paper in preparation), or were nominated by national child neurology societies; (2) having a publication track record in the field of pediatric autoimmune encephalitis/CNS disease; (3) being committed to completing 2 Delphi studies (approximately 45 minutes each),¹⁹,²⁰ and participating in a 2-hour face-to-face/online meeting to reach consensus. The 27 experts were pediatric neurologists (n = 23) or pediatric rheumatologists (n = 4), from North America (n = 9), South America (n = 1), Europe (n = 9), Asia (n = 6), Oceania (n = 1), and Africa (n = 1). In addition, patient representatives (parents, n = 2), a member of the Autoimmune Encephalitis Alliance (n = 1), and adult neurology experts in NMDARE (n = 2, J.D. and S.R.I.) were invited to provide input in the later stages of the process.

Delphi Method
A 2-step Delphi method was adopted to develop the consensus of relevant statements, similar to the method used by the European League Against Rheumatism.²¹ A document with key definitions in pediatric NMDARE (disease severity, failure to improve, and relapse) used in the Delphi statements was shared online with the Panel (January 2020) before the first Delphi questionnaire. A revised version of the modified Rankin Scale²² was used, to be more applicable in children.
Table 1  Definitions Used in the Consensus Recommendations for the Treatment of Pediatric NMDAR Antibody Encephalitis (NMDARE) (Tables 2 and 3)

**Key definitions in pediatric NMDARE**

1.1. Disease severity

Severe is defined by issues affecting SAFETY and FUNCTION. Any (≥1) of the severity markers present below (items a-i) scoring “severe” rather than “standard” would classify as severe disease.

| Markers | Score: severe | Score: standard |
|---------|--------------|-----------------|
| a. Safety | Intensive care | None of |
| Airway support | Dysautonomia threatening safety | |
| b. Mobility | Bed bound | Not bed bound |
| Movement disorder resulting in potential for injury | |
| c. Nursing care | 24/7 support for safety | 24/7 care not required (developmental equivalence) |
| 1 on 1 nurse or parent required for safety | |
| d. Psychiatry | Suicidal thoughts | Psychiatric symptoms are not immediate compromise to safety |
| Dangerous impulse control issues (risk of injury) | |
| Self-injurious behavior | |
| e. Self-care | Unable to self-care, requiring complete assistance (toileting, dressing, and feeding) | Able to self-care (with some assistance or not) |
| f. Communication | Unable to communicate to make themselves understood (including confusion and mutism/aphasia) | Able to communicate and make needs understood |
| g. Alertness | Unresponsive to the immediate environment; blank staring/severe catatonia | Generally able to attend to events in the immediate environment |
| h. Epilepsy | Frequent requirement for rescue medication to terminate seizures | Seizures not requiring intervention with rescue medication |
| i. Adapted mRS score | Adapted mRS score 4-5 | Adapted mRS score 0-3 |

**Adapted modified Rankin Scale (mRS) score**

| Score | Description | Comments |
|-------|-------------|----------|
| 0     | No symptoms | —        |
| 1     | Nondisabling symptoms that do not interfere with the daily activity and playing/learning habits of the child | Playing/learning habits includes attending school or kindergarten |
| 2     | Minor symptoms that lead to some restriction in daily activity and playing/learning habits of the child, but do not interfere with the age-appropriate basic functions | Basic functions: drinking, eating, dressing, undressing, combing, washing, and bathing |
|       | Symptoms: may include minor physical, cognitive, and/or relational symptoms | |
| 3     | Moderate symptoms that significantly interfere with the daily activity and playing/learning habits or prevent total independence in age-appropriate basic functions | Basic functions and symptoms as above |

*Agree % (number voting)*
The first Delphi questionnaire (Delphi 1, eAppendix 1, links.lww.com/NXI/A530) included key statements on the treatment of pediatric NMDARE, which were created based on the steering committee’s clinical practice and the available literature and was sent out to the Panel in February 2020 using a web-based survey tool (SurveyMonkey.com). The Panel members were asked to vote on each statement of the first Delphi questionnaire according to a 5-point Likert scale (strongly agree/agree/neither agree nor disagree/disagree/strongly disagree) and provide open text comments as appropriate. Consensus was defined as an agreement by at least 75% of the participants (i.e., ≥75% agree/strongly agree or ≥75% disagree/strongly disagree).

Twenty-six of 27 experts completed Delphi 1; then, the statements were revised according to the Panel’s responses and comments, and statements that reached consensus were collated into a second Delphi document (Delphi 2). In this second Delphi survey, time durations were added (i.e., total duration of immunotherapy in NMDARE or timing of treatment escalation), and median, interquartile range (IQR), and range were calculated. The Delphi 2 statements were shared with 2 adult experts (J.D. and S.R.I.), with the Autoimmune Encephalitis Alliance representative and family representatives for further input. Delphi 2 was completed by 26 of the 27 experts by online survey in May 2020 (eAppendix 1, links.lww.com/NXI/A530), and final drafted recommendations were created.

Face-to-Face Meeting

The drafted recommendations were then voted on during a 2-hour online consensus meeting via the platform Zoom (zoom.us) on November 3, 2020, and included 26 participants from the expert Panel, with representatives from all continents. Each recommendation was voted on via the platform sli.do with the outcomes agree, do not agree, or abstain. The definitions used in the recommendations and the drug regimens were also voted on for consensus. As before, consensus was defined as an agreement by at least 75% of the participants.

The number of voters varied (22-26 panelists) for the statements due to connectivity issues during the meeting. The statements that reached consensus were collated and are presented.

Data Availability

The Delphi questionnaires used to create the consensus-based recommendations for the treatment of pediatric NMDARE are provided in eAppendix 1 (links.lww.com/NXI/A530).

Results

eAppendix 1 (links.lww.com/NXI/A530) provides the Delphi 1 and Delphi 2 questionnaires and answers. Only final recommendations that reached consensus at the final face-to-
Table 2  Consensus-Based Recommendations on the Treatment of First Event of Pediatric NMDAR Antibody Encephalitis (NMDARE): General Principles (2.1), First-Line Immunotherapy (2.2), Second-Line Immunotherapy (2.3), Maintenance Immune Suppression (2.4), and Overall Duration of Immunotherapy (2.5)

| Statements reaching consensus | Agree % (number voting)* |
|-------------------------------|--------------------------|
| **2.1. General principles in pediatric NMDARE** | |
| **2.1.1.** The management of children with NMDARE should ideally be guided by a pediatric neurology team in a center with multidisciplinary expertise in NMDARE. | 100 (26) |
| **2.1.2.** Priorities are to make an accurate and early diagnosis (exclude alternative diagnoses), initiate appropriate and timely treatment, manage symptoms and complications, support recovery, identify and treat ongoing sequelae, and prevent/treat relapses. | 100 (24) |
| **2.1.3.** All treatment recommendations are subject to absence of contraindications, local experience and availability, and discussion and approval by family. | 100 (25) |
| **2.1.4.** Appropriate management of pediatric NMDARE includes accurate communication and updates with the family, especially regarding suspected diagnosis, uncertainty in treatment responses, need for symptomatic treatment as well as immunotherapy, and challenges in the clinical course. | 100 (24) |
| **2.2. First-line immunotherapy at first event of pediatric NMDARE** | |
| **2.2.1.** First-line immunotherapy should be offered to all children with NMDARE, unless they are already back to baseline at the time of diagnosis (i.e., late diagnosis or rapid improvement and remission). | 100 (25) |
| **2.2.2.** If NMDARE is suspected, immunotherapy should be started promptly, even before antibody results are available, if alternative diagnoses have been reasonably excluded (i.e., infectious encephalitis). | 100 (25) |
| **2.2.3.** IV corticosteroids should be the first immunotherapy used (i.e., IV methylprednisolone, IVMP). If IV corticosteroids are not available or are contraindicated, oral corticosteroids (prednisone, OP or dexamethasone, DEX) should be used. | 96 (25) |
| **2.2.4.** Oral prednisone, oral DEX pulses, or IVMP pulses can be given as an extended taper following an initial course of IVMP, depending on severity, treatment response, and adverse reactions. | 96 (25) |
| **2.2.5.** Therapeutic plasma exchange (TPE) should be strongly considered in patients with severe disease. TPE should precede IV immunoglobulin (IVIg) if both are used. | 84 (25) |
| **2.2.6.** IVIg should be part of the first-line immunotherapy options for all children, especially in severe disease, and can be given with corticosteroids at diagnostic suspicion. | 88 (25) |
| **2.2.7.** In a child who has only received one first-line immunotherapy and who has severe disease or is failing to improve after 1 wk postinitiation of corticosteroids, another first-line immunotherapy (i.e., corticosteroids + TPE or corticosteroids + IVIg) should be considered. | 96 (25) |
| **2.2.8.** In patients who are failing to improve approximately 2 wk after initiation of 2 or more first-line therapies, second-line therapy is favored over further first-line therapies. | 92 (25) |
| **2.2.9.** Prolonged first-line immunotherapy can be offered for up to 3–12 mo, depending on severity and improvement (i.e., especially in countries without access to second-line therapies). Prolonged first-line immunotherapy: corticosteroids (OP, monthly IVMP, and oral DEX pulses), and/or 3–4 weekly IVIg (regardless of initiation of second line). | 92 (24) |
| **2.3. Second-line immunotherapy at first event of pediatric NMDARE** | |
| **2.3.1.** Second-line immunotherapy should be offered to patients with severe disease. | 96 (25) |
| **2.3.2.** Rituximab (RTX) is generally the second-line therapy of choice. Cyclophosphamide (CYC) may be considered if RTX is contraindicated or not available. | 100 (25) |
| **2.3.3.** Another second-line therapy (i.e., CYC, if RTX was used first, or vice versa) can be used in any patient with severe disease who fails to improve adequately 1–3 mo following initiation of the first second-line immunotherapy. | 96 (25) |
| **2.3.4.** Escalation to IV tocilizumab should be considered only in the most refractory patients who fail to improve adequately after about 1–3 mo of treatment with RTX and/or CYC. | 80 (25) |
| **2.4. Maintenance (>6 mo) immune suppression with mycophenolate mofetil (MMF) or RTX redosing after first event of pediatric NMDARE** | |
| **2.4.1.** In general, maintenance immune suppression beyond 6 mo is not typically required. | 88 (24) |
| **2.4.2.** Maintenance (>6 mo) immune suppression can be considered in any patient who fails to improve adequately despite conventional second-line or escalation therapy. | 96 (25) |
| **2.4.3.** RTX redosing (when repopulation of CD19 occurs) and MMF are appropriate treatments if maintenance (>6 mo) immune suppression is required. | 96 (25) |

Continued
Table 2  Consensus-Based Recommendations on the Treatment of First Event of Pediatric NMDAR Antibody Encephalitis (NMDARE): General Principles (2.1), First-Line Immunotherapy (2.2), Second-Line Immunotherapy (2.3), Maintenance Immune Suppression (2.4), and Overall Duration of Immunotherapy (2.5) (continued)

| Statements reaching consensus | Agree % (number voting)* |
|------------------------------|--------------------------|
| 2.4.4. Prolonged first-line therapy (with IVMP, DEX, and IVIG) can be used as an alternative form of maintenance (>6 mo) immunotherapy if RTX and mycophenolate are not available (i.e., in countries without access to other maintenance immunomodulators). | 96 (25) |

2.5. Overall duration of immunotherapy during first event of pediatric NMDARE

2.5.1. In the absence of clinical relapse, the overall duration of total immunotherapy (including all first line, second line, and maintenance, i.e., IVMP to completion of MMF, or to B-cell repopulation after RTX) depends on the severity of the clinical picture, the response to first- and second-line or escalation immunotherapy, and treatment adverse reactions.

As a guideline:
- Median 3 mo (IQR 3–6 mo, range 1–18 mo), in the best responders (without relapse or adverse reactions)
- Median 9 mo (IQR 6–12 mo, range 1–24 mo), in the average responders (without relapse or adverse reactions)
- Median 18 mo (IQR 12–24 mo, range 1–25 mo), in the poorest responders (without relapse or adverse reactions).

Definitions of failure to respond, and timing of treatment escalation. Indeed, although the management of pediatric NMDARE should ideally be guided by a pediatric neurology team in a center with multidisciplinary expertise in NMDARE, this may not always be possible, particularly in the acute phase of the disease.

Our recommendations begin with general management principles, highlighting the importance of early diagnosis and careful communication with the family (Table 2, 2.1). The importance of raising awareness of this disorder, which may present to psychiatrists and emergency physicians as well as neurologists, cannot be overemphasized, and the diagnostic criteria and modifications for children, along with the distinctive clinical characteristics, may aid in an expeditious diagnosis. Similarly, families need to be informed of the expected or potential disease evolution, the treatment possibilities, and the often long and demanding course of the illness. Understanding the timeline of the disease and the speed of recovery is one of the greatest challenges of this disease, and it is essential for clinicians and family members to appreciate that the typical course is of little change (or worsening) in the first weeks and slow improvements in the following months, and improvements may continue into the second year.

As regards first-line immunotherapy (Table 2, 2.2), there was consensus that corticosteroids are the first agent to be used in pediatric NMDARE, with IV use (i.e., IV methylprednisolone) preferred over oral use (i.e., oral prednisone), although high-dose oral administration of corticosteroids is a good alternative, particularly if IV access is a problem. In high-income countries, therapeutic plasma exchange (TPE) and/or IV immunoglobulin (IVIg) are often used in conjunction with corticosteroids. Although some physicians use TPE or IVIg at the same time as corticosteroids, other administer them sequentially, with more
Table 3 Consensus-Based Recommendations on the Treatment of Pediatric NMDAR Antibody Encephalitis (NMDARE): NMDARE Relapse (3.1), Herpes Simplex Virus Encephalitis Followed by NMDARE (3.2), Symptomatic Therapies (3.3), and Oncologic Searches (3.4)

| Statements reaching consensus | Agree % (number voting)a |
|-------------------------------|--------------------------|
| 3.1. Pediatric NMDARE relapse: first-line, second-line immunotherapy, and maintenance (>6 mo) immune suppression | 100 (25) |
| 3.1.1. First-line immunotherapy should be offered to all children with NMDARE relapse, even if they are improving at the time of diagnosis (i.e., late diagnosis or rapid improvement and remission). First-line immunotherapy and combinations can be used as per Table 2, 2.2. | 96 (25) |
| 3.1.2. In patients who relapse, second-line immunotherapy and/or maintenance (>6 mo) immunosuppression (mycophenolate mofetil or rituximab [RTX] redosing) should be considered, started within median 2 wk after initiation of first-line treatment (range 1–3 wk).b | 88 (25) |
| 3.1.3. Although generally only one second-line treatment is used, another second-line treatment (i.e., cyclophosphamide [CYC], if RTX was used first, or vice versa) can be used in patients who fail to improve after relapse. | 88 (25) |
| 3.1.4. In patients with NMDARE relapse, escalation to IV tocilizumab should be considered only in the most refractory patients who fail to improve adequately after about 1–3 mo of treatment with RTX and/or CYC. | 84 (25) |
| 3.1.5. Duration of maintenance immunosuppression in patients with relapse should be 12–24 mo depending on the severity of the clinical picture, the response to first- and second-line immunotherapy, the number of relapses, and treatment adverse reactions. | 88 (25) |
| 3.1.6. If NMDARE relapse occurs while on maintenance immunosuppression (RTX redosing, mycophenolate, or prolonged first-line treatment) given for first event, prompt first-line immunotherapy should be administered (i.e., IV methylprednisolone and/or therapeutic plasma exchange/IV immunoglobulin), followed by second-line treatment and alternative maintenance immunosuppression. | 84 (25) |
| 3.2. Herpes simplex virus encephalitis (HSE) followed by NMDARE in children |  |
| 3.2.1. Patients with relapse of neurologic symptoms after HSE should be given acyclovir promptly (until HSE can be excluded based on clinical picture and negative CSF herpes simplex virus PCR), while maintaining a high index of suspicion for an underlying autoimmune etiology. | 84 (25) |
| 3.2.2. Patients with NMDARE following HSE should be treated with immunotherapy in a similar way to those with naive NMDARE. | 96 (25) |
| 3.3. Symptomatic therapies for pediatric NMDARE |  |
| 3.3.1. Assessment of improvement following immunotherapy (i.e., failure to improve) is contingent on optimization of treatments for sleep, agitation, mood/behavior, dyskinesia, and seizures. |  |

Table 3 Continued

| Statements reaching consensus | Agree % (number voting)a |
|-------------------------------|--------------------------|
| 3.3.2. Use of antipsychotics and management of psychiatric symptoms should be undertaken in collaboration with a child psychiatrist. It should be remembered that the use of antipsychotics in children with NMDARE may be associated with a worsening of dyskinesia or result in neuroleptic malignant syndrome. | 92 (25) |
| 3.3.3. In descending order of recommendation, the following agents can be useful in the symptomatic management of agitation: benzodiazepines, sleep induction agents (chloral hydrate or melatonin), alpha adrenergic agents (clonidine and dexamethasone), and atypical antipsychotics (risperidone, olanzapine, and quetiapine).d | 88 (24) |
| 3.3.4. In descending order of recommendation, the following agents can be useful in the symptomatic management of dyskinesia and stereotypy: alpha adrenergic agents (clonidine and dexamethasone), benzodiazepines, antiepileptics (valproate, carbamazepine, and gabapentin), anticholinergic agents, and sleep induction (chloral hydrate or melatonin).d |  |
| 3.4. Oncologic searches |  |
| 3.4.1. Tumor searches for ovarian teratoma and other tumors are mandatory in all children with NMDARE, should be started early, and be completed in the first days to weeks after admission. If tumor is found, removal is required as this can result in rapid improvements. | 100 (25) |
| 3.4.2. Generally recommended tumor searches include the following: | 88 (25) |
| Ovarian/testicular ultrason and/or MRI abdomen and pelvis (in all patients) |  |
| Urinary catecholamines and/or CT or MRI of the chest (in very young patients aged <5 y)6 |  |
| It is important to consult oncologists and radiologists for best imaging modality to search occult tumors. |  |
| 3.4.3. Recommended duration for tumor searches (if no tumor found on initial searches) is: | 92 (26) |
| • In patients with good recovery: |  |
| o Prepubertal females and all males: only at diagnosis |  |
| o Postpubertal females: annually up to 2 y |  |
| • In all patients who fail to improve adequately, or relapse: annually up to 5 y (or at the time of relapse). |  |

* The agreement percentage shown in the last column refers to the final face-to-face agreement; the Delphi 1 and 2 agreement percentages are shown in eAppendix 1 (links.lww.com/NXI/A350).
* Due to the possible presence of neural crest tumor.
* The timelines were voted on during the Delphi process (eAppendix 1).
* These agents were voted on during the Delphi process (eAppendix 1). All the listed agents were supported by different members of the Panel, but only benzodiazepines and sleep induction agents reached 75% consensus support (eAppendix 1).

severe patients often prompting a more aggressive combined treatment or rapid escalation. TPE was recommended for patients with severe disease, although it is recognized that TPE can be associated with more severe complications (e.g., central line

Neurology.org/NN Neurology: Neuroimmunology & Neuroinflammation | Volume 8, Number 5 | 0 0 7
infection) compared with IVIg. TPE was recommended over immunoadsorption, where there is less evidence. In general, ongoing corticosteroids are continued in the first months of disease, preferably as pulses, or alternatively oral tapers. Longer or repeated IVIg courses may be continued monthly for 3–6 months, depending on severity and availability, whereas monthly pulsed oral dexamethasone or IV methylprednisolone, or even ACTH, for 3-6 months may be used in resource-limited settings.

In patients who are failing to improve (definition in Table 1) approximately 2 weeks after initiation of 2 or more first-line therapies, second-line treatment is recommended over further first-line therapies. Second-line treatments are recommended especially in patients with severe disease, with rituximab now generally preferred over cyclophosphamide (Table 2, 2.3). Rituximab dosing protocols were all equally accepted (Table 4) as there are no data to support one protocol over another. There is evidence suggesting that use of second-line immunotherapy improves outcome in patients failing to improve after first-line therapy and that second-line therapy reduces the risk of relapses. Moreover, earlier initiation of rituximab also seems more favorable compared with late treatment.

The use of second-line immunotherapy is still variable globally and considerably less frequent in some countries. For instance, rituximab use is 0%–5.5% in Chinese cohorts and more variable in India (0%–61%), although with generally favorable outcomes, which suggests the outcomes described in the published literature may be affected by referral bias, publication bias, or ethnic vulnerability to worse outcomes. The specific approaches toward the use of second-line immunotherapy varied within the Panel, with some clinicians supporting the use of rituximab in all patients with NMDARE and others reserving it to cases with severe disease or failure to improve (Table 1). The consensus

### Table 4 Treatment Regimens and Doses for Pediatric NMDAR Antibody Encephalitis (NMDARE) (95% Agreement, 22 Voting—Final Face-to-Face Agreement)

| Immunotherapies       | Type of use                                      | Dose/mode of administration                                                                 |
|-----------------------|--------------------------------------------------|------------------------------------------------------------------------------------------------|
| IV methylprednisolone | First-line immunotherapy                         | 20–30 mg/kg/d (max 1 g/d) for 3–5 d                                                          |
|                       | Prolonged first-line immunotherapy               | 20–30 mg/kg/d (max 1 g/d) for 1–3 d, monthly                                                 |
| Oral prednisone       | First-line immunotherapy: alternative to IV corticosteroids | 2 mg/kg/d (max 60 mg/d) for 1 wk, then gradually tapered (see main guideline)               |
|                       | First-line immunotherapy: taper after IV corticosteroids | 2 mg/kg/d (max 60 mg/d) for 1 wk, then gradually tapered (see main guideline)               |
|                       | Prolonged first-line immunotherapy               | 2 mg/kg/d (max 60 mg/d) for 1 wk, then gradually tapered (see main guideline)               |
| Oral dexamethasone    | First-line immunotherapy: alternative to IV corticosteroids | 20 mg/m²/d (divided into 2 or 3 doses, max 12 mg tid) for 3 d                              |
|                       | First-line immunotherapy: taper after IV corticosteroids | 20 mg/m²/d (divided into 2 or 3 doses, max 12 mg tid) for 3 d, every 3–4 wk                |
|                       | Prolonged first-line immunotherapy               | 20 mg/m²/d (divided into 2 or 3 doses, max 12 mg tid) for 3 d, every 3–4 wk                |
| Therapeutic plasma exchange | First-line immunotherapy                | One course is typically 5–7 single or double plasma volume exchanges over 7–10 d             |
| IV immunoglobulin     | First-line immunotherapy                         | 2 g/kg over 2–5 d                                                                            |
|                       | Prolonged first-line immunotherapy               | 1–2 g/kg over 1–2 d, monthly                                                                 |
| IV rituximab          | Second-line immunotherapy                        | The following doses are acceptable:                                                          |
|                       | Maintenance (>6 mo) immune suppression            | Rituximab redosing (same doses as above or reduced dose as per local recommendations)       |
|                       | Maintenance (>6 mo) immune suppression            | when repopulation of CD19 occurs (or about 6 mo after the first course)                     |
| IV cyclophosphamide   | Second-line immunotherapy                        | 500–1,000 mg/m² (max 1,500 mg)23–25 monthly pulses for up to 6 mo                           |
| Oral mycophenolate mofetil | Maintenance (>6 mo) immune suppression | 600 mg/m²/dose (max 1 g/dose) twice a day                                                   |
| IV tocilizumab        | Escalation second-line immunotherapy              | 12 mg/kg/dose (<30 kg), 8 mg/kg/dose (≥30 kg) (max 800 mg) given monthly over 6 mo or more (duration of required immunosuppression) |

8 Neurology: Neuroimmunology & Neuroinflammation | Volume 8, Number 5 | 0 0 Neurology.org/NN
opinion was that second-line therapy is not needed in all patients, but only in patients with severe disease and those who fail to improve.

One of the greatest challenges is deciding the timing of escalation after 1 second-line therapy. There was consensus that in the patient failing to improve 1-3 months (generally >6
weeks) following initiation of the first second-line immunotherapy, another second-line therapy such as cyclophosphamide if rituximab was used first can be considered.

In the patient who fails rituximab, cyclophosphamide is generally recommended as an escalation agent, although some members of the Panel have increasing interest in tocilizumab as an alternative escalation therapy due to a more favorable perceived safety profile. Other escalation treatments have been reported in the literature, such as IV/intrathecal methotrexate with intrathecal corticosteroids and subcutaneous/IV bortezomib; these have more limited evidence, but can be used according to the local treating center’s expertise.

The patient who has severe disease and is failing to improve remains a major challenge. The clinician needs to balance the risk of severe disease (such as being on the intensive care unit) with the risk of treatment side effects, in the knowledge that NMDARE symptoms may take many weeks or months to improve. Indeed, unlike in acute disseminated encephalomyelitis, when treatment often results in rapid improvements within days, in NMDARE, the improvements are slow and continue for >24 months after the acute phase. Therefore, allowing treatments to have their effect, including their combined actions, is important to avoid hasty therapeutic decisions. In general, second-line agents such as rituximab or cyclophosphamide should be given 1-3 months before making judgment on effect, with 6 weeks being a broadly accepted guideline. The timing of escalation is very challenging and influenced by severity, age, risk-benefit ratio, treating center’s experience, and access to treatments. Overall, for patients in the intensive care unit, where there may be multiple additional risk factors, earlier escalation seems reasonable. Anecdotal reports from our expert group of benefit of treatment with rituximab or tocilizumab years after onset suggest that in the patient who continues to have major impairments, further immunotherapies are warranted within reason, although there are likely to be diminishing returns when treatment is used later in the disease course.

In the patient who has failed to improve a year or more after treatment, it is sometimes difficult to determine residual sequelae from ongoing inflammation. In this situation, CSF re-examination for ongoing neuroinflammation (i.e., persistent pleocytosis, intrathecal oligoclonal bands, elevated immunoglobulin G [IgG] index, or CSF neopterin) may help with decision making and the risk vs benefit consideration of an empiric retrial or immunotherapy (pulsed corticosteroid for 3 months, IVlg monthly, rituximab reinduction, or tocilizumab). CSF NMDAR antibody titers seem to correlate better with disease course compared with serum antibodies, but there is not a strong correlation between titer and clinical course in the individual patient, and antibodies can persist long after recovery.

Although all stages of management of NMDARE may be challenging even for experienced physicians, this is especially true when dealing with a severe patient failing to improve, and a second opinion may be useful and help the clinician make further therapeutic decisions. Organizations such as the Autoimmune Encephalitis Alliance (encephalitis.info/), the Encephalitis Society (encephalitis.info/), and the Anti NMDA Receptor Encephalitis Foundation Inc. (antimndafoundation.org/) may help connect with experts.

There was overall agreement that maintenance immune suppression beyond 6 months from onset is generally not needed (Table 2, 2.4), apart from patients with more severe course or prolonged impairments and hospitalization. Indeed, literature data show that early and adequate treatment, including use of second-line therapies when appropriate, is the priority, rather than prolonged maintenance immune suppression. Moreover, the relatively low relapse rate of NMDARE is in significant contrast with that of other disorders such as neuromyelitis optica, where chronic immune suppression is recommended from the first event. When giving immune suppression for more than 6 months, rituximab redosing was generally preferred, although mycophenolate mofetil is also used, and there is little evidence to suggest superiority of either. With regard to rituximab redosing, most experts recommend redosing when CD19 cells repopulate, in view of the variability in the time to B-cell repopulation between individuals. An alternative approach is to redose rituximab at regular 6-month intervals similar to practice in adult patients with neuromyelitis optica. There was no consensus in the dosage and frequency of redosing, with some experts using the same dose/
regimen used at induction and others using lower doses (Table 4). As regards mycophenolate mofetil, given its slow onset of efficacy, there should initially be overlap with other immunotherapies (i.e., oral corticosteroids) for 3–6 months after commencement. Other maintenance agents, such as oral azathioprine and methotrexate, are sometimes used for maintenance immune suppression, although the paucity of experience precluded consensus recommendations from our expert group. In resource-poor countries, the Panel also agreed that prolonged first-line therapy (with IV pulsed methylprednisolone, dexamethasone, or IVlg) can be used as an alternative form of maintenance (>6 months) immunotherapy, if rituximab and mycophenolate mofetil are not available.

There was agreement in the need for a more aggressive and prolonged treatment approach in patients with relapsing disease (Table 3, 3.1), with a lower threshold for second-line and maintenance treatments (rituximab or mycophenolate) and more prolonged overall immunotherapy duration. Indeed, the median overall duration of immunotherapy at first event of pediatric NMDARE was recommended to be about 3 months (IQR 3–6 months) in the best responders, 9 months (IQR 6–12 months) in the average responders, 18 months (IQR 12–24 months) in the poorest responders (Table 2, 2.5), and 12–24 months after a relapse, acknowledging patient severity and management variables (Table 3, 3.1). We acknowledge that the definition of “best,” “average,” and “poorest” is dependent on experience of the clinician; therefore, some guidance is provided in Table 5.

Although not the focus of this work, the Panel acknowledges that infectious risk mitigation strategies are key to ensure the patients’ safety while receiving immunotherapy, especially close monitoring for infections and adherence to hospital infection control protocols to prevent hospital acquired infection. In selected patients on prolonged high-dose corticosteroids, multiple second-line or escalation immunotherapies, prophylactic trimethoprim-sulfamethoxazole for Pneumocystis carinii pneumonia may be required. In patients with low IgG levels and recurrent infections despite prophylactic antibiotics, immunoglobulin supplementation may be required.

As regards patients with relapse of neurologic symptoms after HSE (Table 3, 3.2), acyclovir should be administered promptly until HSE recurrence is excluded, while maintaining a high index of suspicion for an underlying autoimmune etiology. The Panel agreed that if autoimmune encephalitis is confirmed after HSE, immunotherapy should be used in a similar way to idiopathic/naive NMDARE.

The Panel acknowledged that although immunotherapy is the therapeutic priority to treat the underlying disease, symptomatic management (such as antiseizure medications) is equally important (Table 3, 3.3). However, symptom management may be challenging and requires multidisciplinary expertise. As stated in the recommendations, there was consensus on a preferred list of medications found to be useful in the treatment of behavior agitation and dyskinesia (full list of medications considered is detailed in eAppendix 1, links.lww.com/NXI/A330). Caution was also drawn to the observation that the use of antipsychotics in pediatric NMDARE may worsen dyskinesia or induce a neuroleptic malignant syndrome.

Although paraneoplastic etiology is rare in prepubertal children and in boys, oncologic searches for ovarian teratoma (and neural crest tumors in children aged <5 years) are mandatory in all children with NMDARE, should be performed early, and be completed in the first days-weeks after admission (Table 3, 3.4). Ultrasound or MRI of the abdomen and pelvis or CT or MRI of the chest are the recommended imaging modalities, and collaboration with local oncologists and radiologists will help guide the need for additional studies (e.g., PET scan) to optimize diagnostic yield in patients with severe disease or a failure to improve. The timely identification of a tumor and its subsequent removal may improve the outcome considerably, although the prognosis also depends on the type of tumor. The Panel reached agreement on oncologic searches that should be performed in all patients, both at baseline and in patients who fail to improve or relapse, with particular focus on postpubertal females in whom ovarian teratoma screening and longitudinal surveillance for ovarian teratoma should be strongly pursued.

Although not the main aim of this consensus document, the Panel acknowledged that adequate rehabilitation after the acute phase of NMDARE is essential and may improve outcomes. We strongly support the need for rehabilitation to be provided in a center familiar with rehabilitating young people with acquired brain injury such as encephalitis or traumatic brain injury, acknowledging that improvements may continue for up to 24 months. Rehabilitation often includes focus on cognitive and behavioral problems (including executive dysfunction and fatigue) post-NMDARE.

In view of the relative rarity of this condition, any recommendation or guideline for the treatment of pediatric NMDARE is inevitably based on limited evidence; therefore, this document should be intended as a recommendation meant to provide guidance rather than absolute rules, and it should not be used to prevent access to therapies if these are recommended by a patient’s physician. Moreover, by putting together international experts from very different settings, the present work highlighted heterogeneity in the management of this condition. The differences stimulated discussion and reflection, and there was still consensus around most aspects of pediatric NMDARE treatment. Although the experts included people with broad international expertise, the opinions remain vulnerable to anecdote and potential bias related to referral of complicated or atypical patients.

Despite these limitations, we strove to create an international consensus-based recommendation aimed at supporting the clinician in the treatment of pediatric NMDARE, with a dedicated global approach for all health care settings. We hope that with the aid of recently released diagnostic criteria,
the present treatment recommendation may contribute to a more systematic approach, resulting in more comparable data internationally, which may generate better quality evidence. Nonetheless, there are still major unresolved issues, which should represent the focus of future research.

**Acknowledgment**

The authors thank Kimberley de Haseth from AEA and the De Vivero family for support and advice.

**Study Funding**

There was funding commitment for the face to face meeting by the Autoimmune Encephalitis Alliance (AEA), which due to COVID-19 was not needed, as the face-to-face meeting was virtual. AEA has supported costs of open access for journal publication. M. Eyre is supported by Action Medical Research and the British Paediatric Neurology Association. T. Armangue is supported by research grants Instituto Carlos III/FEDER, Spain (PI18/00486) and Generalitat de Catalunya PERIS (SLT006/17/00362). S.R. Irani is supported by the Wellcome Trust (104079/Z/14/Z), the UCB-Oxford University Alliance, BMA Research Grants Vera Down grant (2013) and Margaret Temple (2017), Epilepsy Research UK (PI201), the Fulbright UK-US commission (MS-Society research award), and by the NIHR Oxford Biomedical Research Centre. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health). RCD is supported by NHMRC Investigator grant (Australia) and Petre Foundation.

**Disclosure**

M. Nosadini, T. Thomas, M. Eyre, B. Anlar, T. Armangue, S.M. Benseler, T. Cellucci, K. Deiva, and W. Gallentine report no disclosures relevant to the manuscript. G. Gombolay receives part-time salary support from the Centers for Disease Control and Prevention to review acute flaccid myelitis cases for surveillance. M.P. Gorman has received research funding from Pfizer and Roche for research unrelated to the current topic. Y. Hacohen, Y. Jiang, B.C. Lim, E. Muscal, and A. Ndondo report no disclosures relevant to the manuscript. R. Neuteboom participates in treatment studies in pediatric MS by Novartis and Sanofi-Genzyme and received consultation fees from Novartis, Zogenix, and Sanofi-Genzyme. K. Rostásy, H. Sakuma, and S. Sharma report no disclosures relevant to the manuscript. S.N. Tenenbaum participates as member of the NMO Scientific Advisory Committee (Genentech-Roche Inc.) and chair of the NMO Relapse Adjudication Committee (Alexion Pharmaceuticals Inc.); she has received speaker honoraria from Biogen Idec Argentina, Merck Serono LATAM, Genzyme, Novartis Argentina, and Novartis Pharma Inc. H.A. Van Mater and E. Wells report no disclosures relevant to the manuscript. R. Wickstrom has received consultation fees from Roche, Novartis, and Octapharma. A.K. Yeshokumar reports no disclosures relevant to the manuscript. S.R. Irani is a coapplicant and receives royalties on patent application WO/210/046716 (U.K. patent no., PCT/GB2009/051441) entitled “Neurological Autoimmune Disorders” (the patent has been licensed for the development of assays for LGI1 and other VGKC-complex antibodies) and on an unlicensed patent to improve detection of autoantibodies. J. Dalmau reports no disclosures relevant to the manuscript. M. Lim has received consultation fees from CSL Behring, Novartis, and Octapharma; travel grants from Merck Serono; and was awarded educational grants to organize meetings by Novartis, Biogen Idec, Merck Serono, and Bayer. R.C. Dale reports no disclosures relevant to the manuscript. Go to Neurology.org/NN for full disclosures.

**Publication History**

Received by Neurology: Neuroimmunology & Neuroinflammation February 14, 2021. Accepted in final form May 21, 2021.

**Appendix Authors**

| Name                  | Location                                                                 | Contribution                                                                 |
|-----------------------|---------------------------------------------------------------------------|------------------------------------------------------------------------------|
| Margherita Nosadini,  | Paediatric Neurology and Neurophysiology Unit, Department of Women's and   | Literature review; participation to the Delphi process and the final online   |
| MD, PhD               | Children's Health, University Hospital of Padova, Italy                    | face-to-face meeting for creation of the consensus treatment statements;      |
|                       |                                                                           | preparation of the recommendation draft; technical support, data analysis;   |
|                       |                                                                           | preparation of the recommendation draft; and editing and approval of the     |
|                       |                                                                           | final draft                                                                  |
| Terrence Thomas, MD   | Department of Paediatrics, Neurology Service, KK Women's and Children's    | Participation to the Delphi process and the final online face-to-face meeting|
|                       | Hospital, Singapore                                                      | for creation of the consensus treatment statements; technical support, data   |
|                       |                                                                           | analysis; preparation of the recommendation draft; and editing and approval  |
|                       |                                                                           | of the final draft                                                           |
| Michael Eyre, MD      | Department of Paediatric Neurology, Great Ormond Street Hospital for      | Participation to the Delphi process and the final online face-to-face meeting|
|                       | Children, London, United Kingdom                                         | for creation of the consensus treatment statements; technical support, data   |
|                       |                                                                           | analysis; preparation of the recommendation draft; and editing and approval  |
|                       |                                                                           | of the final draft                                                           |
| Banu Anlar, MD        | Department of Pediatric Neurology, Hacettepe University, Ankara, Turkey   | Participation to the Delphi process and the final online face-to-face meeting|
|                       |                                                                           | for creation of the consensus treatment statements and revision of the        |
|                       |                                                                           | manuscript for intellectual content                                          |
| Thais Armandegue,     | Neuroimmunology Program, Institut d'Investigacions Biomediques August Pi i | Participation to the Delphi process and the final online face-to-face meeting|
| MD, PhD               | Sunyer (IDIBAPS), Hospital Clinic, Universitat de Barcelona, Spain;       | for creation of the consensus treatment statements and revision of the        |
|                       | Pediatric Neuroimmunology Unit, Neurology Department, Sant Joan de Òeú   | manuscript for intellectual content                                          |
|                       | (SJD) Children's Hospital, University of Barcelona, Spain                 |                                                                               |
## Appendix (continued)

| Name                  | Location                                                                 | Contribution                                                                 |
|-----------------------|---------------------------------------------------------------------------|------------------------------------------------------------------------------|
| Susanne M. Benseler, MD | Alberta Children's Hospital Research Institute, Department of Pediatrics, Cumming School of Medicine, University of Calgary, Canada | Participation to the Delphi process and the final online face-to-face meeting for creation of the consensus treatment statements and revision of the manuscript for intellectual content |
| Tania Cellucci, MD, FRCPC, MSCH | Division of Rheumatology, Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada | Participation to the Delphi process and the final online face-to-face meeting for creation of the consensus treatment statements and revision of the manuscript for intellectual content |
| Kumaran Deiva, MD | Assistance Publique-Hôpitaux de Paris, Pediatric Neurology Department, University Hospitals Paris Saclay, Bicêtre Hospital, France; French Reference Network of Rare Inflammatory Brain and Spinal Diseases, Le Kremlin Bicêtre, France and European Reference Network-RITA, France | Participation to the Delphi process and the final online face-to-face meeting for creation of the consensus treatment statements and revision of the manuscript for intellectual content |
| William Gallentine, DO | Departments of Neurology and Pediatrics, Stanford University and Lucile Packard Children's Hospital, Palo Alto, CA | Participation to the Delphi process and the final online face-to-face meeting for creation of the consensus treatment statements and revision of the manuscript for intellectual content |
| Grace Gombolay, MD | Division of Pediatric Neurology, Department of Pediatrics, Emory University School of Medicine and Children's Healthcare of Atlanta, GA | Participation to the Delphi process and the final online face-to-face meeting for creation of the consensus treatment statements and revision of the manuscript for intellectual content |
| Mark P. Gorman, MD | Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, MA | Participation to the Delphi process and the final online face-to-face meeting for creation of the consensus treatment statements and revision of the manuscript for intellectual content |
| Yael Hacohen, MD | Department of Neuroinflammation, Queen Square MS Centre, UCL Institute of Neurology, University College London; Department of Paediatric Neurology, Great Ormond Street Hospital for Children, London, United Kingdom | Participation to the Delphi process and the final online face-to-face meeting for creation of the consensus treatment statements and revision of the manuscript for intellectual content |
| Yuwu Jiang, MD | Department of Pediatrics, Peking University First Hospital, Beijing, China | Participation to the Delphi process for creation of the consensus treatment statements and revision of the manuscript for intellectual content |
| Byung Chan Lim, MD | Department of Pediatrics, Pediatric Clinical Neuroscience Center, Seoul National University Children's Hospital, Seoul National University College of Medicine, South Korea | Participation to the Delphi process and the final online face-to-face meeting for creation of the consensus treatment statements and revision of the manuscript for intellectual content |
| Eyal Muscal, MD, MS | Department of Pediatrics, Section Rheumatology, co-appointment in the section of Neurology and Developmental Neuroscience, Texas Children's Hospital, Baylor College of Medicine, Houston, TX | Participation to the Delphi process and the final online face-to-face meeting for creation of the consensus treatment statements and revision of the manuscript for intellectual content |
| Alvin Ndondo, MD | Division of Paediatric Neurology, Department of Paediatrics and Child Health, Red Cross War Memorial Children's Hospital, University of Cape Town; Faculty of Health Sciences, University of Cape Town Neuroscience Institute, South Africa | Participation to the Delphi process and the final online face-to-face meeting for creation of the consensus treatment statements and revision of the manuscript for intellectual content |
| Rinze Neuteboom, MD, PhD | Department of Neurology, Erasmus Medical Center, Rotterdam, the Netherlands | Participation to the Delphi process and the final online face-to-face meeting for creation of the consensus treatment statements and revision of the manuscript for intellectual content |
| Kevin Rostasy, MD | Department of Pediatric Neurology, Children's Hospital Datteln, University Witten/Herdecke, Germany | Participation to the Delphi process and the final online face-to-face meeting for creation of the consensus treatment statements and revision of the manuscript for intellectual content |
| Hiroshi Sakuma, MD | Department of Brain and Neural Science, Tokyo Metropolitan Institute of Medical Science, Japan | Participation to the Delphi process and the final online face-to-face meeting for creation of the consensus treatment statements and revision of the manuscript for intellectual content |
| Suvasini Sharma, MD | Department of Pediatrics (Neurology Division), Lady Hardinge Medical College and Associated Kalawati Saran Children's Hospital, New Delhi, India | Participation to the Delphi process and the final online face-to-face meeting for creation of the consensus treatment statements and revision of the manuscript for intellectual content |
| Silvia Noemi Tenembaum, MD | Department of Neurology, National Pediatric Hospital Dr. J. Garrahan, Buenos Aires, Argentina | Participation to the Delphi process and the final online face-to-face meeting for creation of the consensus treatment statements and revision of the manuscript for intellectual content |
| Heather Ann Van Mater, MD | Department of Pediatrics, Duke University, Durham, NC | Participation to the Delphi process and the final online face-to-face meeting for creation of the consensus treatment statements and revision of the manuscript for intellectual content |
| Elizabeth Wells, MD | Department of Neurology, Children's National Medical Center, Washington, DC | Participation to the Delphi process and the final online face-to-face meeting for creation of the consensus treatment statements and revision of the manuscript for intellectual content |

Continued
Appendix (continued)

| Name                | Location                                                                 | Contribution                                                                 |
|---------------------|---------------------------------------------------------------------------|------------------------------------------------------------------------------|
| Ronny Wickstrom, MD, PhD | Neuropaediatric Unit, Karolinska University Hospital, Stockholm, Sweden | Participation to the Delphi process and the final online face-to-face meeting for creation of the consensus treatment statements and revision of the manuscript for intellectual content |
| Anusha K. Yeshokumar, MD | Department of Neurology, Icahn School of Medicine at Mount Sinai, New York | Participation to the Delphi process and the final online face-to-face meeting for creation of the consensus treatment statements and revision of the manuscript for intellectual content |
| Sarosh R. Irani, MD, PhD | Oxford Autoimmune Neurology Group, Nuffield Department of Clinical Neurosciences, University of Oxford, John Radcliffe Hospital, Department of Neurology, Oxford University Hospitals NHS Foundation Trust, United Kingdom | Expert guidance and revision of the manuscript for intellectual content |
| Josep Dalmau, MD, PhD | Neuroimmunology Program, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clinic, University of Barcelona, Spain; Department of Neurology, University of Pennsylvania, Philadelphia | Expert guidance and revision of the manuscript for intellectual content |
| Ming Lim, MD, PhD | Children's Neurosciences, Evelina London Children's Hospital at Guy's and St Thomas' NHS Foundation Trust; King's Health Partners Academic Health Science Centre, London; Faculty of Life Sciences and Medicine, King's College Hospital, London, United Kingdom | Participation to the Delphi process and the final online face-to-face meeting for creation of the consensus treatment statements; preparation of the recommendation draft; and editing and approval of the final draft |
| Russell C. Dale, MD, PhD | Kids Neuroscience Centre, The Children's Hospital at Westmead, Faculty of Medicine and Health, University of Sydney, NSW, Australia | Project conception and design; literature review; participation to the Delphi process and the final online face-to-face meeting for creation of the consensus treatment statements; preparation of the recommendation draft; and editing and approval of the final draft; and access to all the data and responsibility for the data, accuracy of the data analysis, and the conduct of the research |

References
1. Dalmau J, Gleichman AJ, Hughes EG, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol. 2008;7(12):1091-1098.
2. Titulaer MJ, McCracken L, Gaboludo I, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol. 2013;12(2):157-165.
3. de Bruijn MAAM, Aarsen FK, van Oosterhout MP, et al. Long-term neuro-psychological outcome following pediatric anti-NMDAR encephalitis. Neurology. 2018;90(22):e2005.
4. Irani SR, Bera K, Waters P, et al. N-methyl-D-aspartate encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain. 2010;133(pt 6):1655-1667.
5. Hacohen Y, Absoud M, Hemingway C, et al. NMDA receptor antibodies associated with distinct white matter syndromes. Neurol Neuroimmunol Neuroinflammm. 2014;1(1):e2.
6. Byrne S, Walsh C, Hacohen Y, et al. Earlier treatment of NMDAR antibody encephalitis in children results in a better outcome. Neurol Neuroimmunol Neuroinflammm. 2015;2(4):e130.
7. Dale RC, Brilot F, Duffy LV, et al. Utility and safety of Rituximab in pediatric autoimmune and inflammatory CNS disease. Neurology. 2014;83(2):142-150.
8. Gaboludo I, Sair A, Galin L, et al. Analysis of relapses in anti-NMDAR encephalitis. Neurology. 2011;77(10):996-999.
9. Nosadini M, Granata T, Maticardi S, et al. Relapse risk factors in anti-N-methyl-D-aspartate receptor encephalitis. Dev Med Child Neurol. 2019;61(9):1101-1107.
10. Bartolini L, Muscal E. Differences in treatment of anti-NMDA receptor encephalitis: results of a worldwide survey. J Neurol. 2017;264(4):647-653.
11. Kahn I, Helman G, Vandermeer A, Welle E. Anti-N-methyl-d-aspartate (NMDA) receptor encephalitis. J Child Neurol. 2017;32(2):243-245.
12. Dalmau J, Lancaster E, Martinez-Hernandez E. Rosalind MR, Balice-Gordon R. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol. 2011;10(3):63-74.
13. Nosadini M, Mohammad SS, Ramanathan S, Brilot F, Dale RC. Immune therapy in autoimmune encephalitis: a systematic review. Expert Rev Neurother. 2015;15(12):1391-1419.
14. Lancaster E. The diagnosis and treatment of autoimmune encephalitis. J Clin Neurol. 2016;12(1):1-13.
15. Dale RC, Gorman MP, Lim M. Autoimmune encephalitis in children: clinical phenomenology, therapeutics, and emerging challenges. Curr Opin Neurol. 2017;30(3):334-344.
16. Shin YW, Lee ST, Park KL, et al. Treatment strategies for autoimmune encephalitis. Ther Adv Neurol Disord. 2017;11:175628617723247.
17. Zuliani L, Nosadini M, Gastaldi M, et al. Management of antibody-mediated autoimmune encephalitis in adults and children: literature review and consensus-based practical recommendations. Neurol Sci. 2019;40(10):2013-2030.
18. Dalmau J, Armangue T, Planagumà J, et al. An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: mechanisms and models. Lancet Neurol. 2019;18(13):1045-1057.
19. Linstone HA, Turroff M, eds. The Delphi Method Techniques and Applications. Addison-Wesley. 1975.
20. Hawn F, Keeney S, McKenna H. Research guidelines for the Delphi survey technique. J Adv Nurs. 2000;32(4):1008-1015.
21. ter Haar NM, Oswald M, Jeyaratnam J, et al. Recommendations for the management of autoimmune and paraneoplastic encephalitis. Ann Rheum Dis. 2015;74(9):1636-1644.
22. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver variability of the modified Rankin scale in a population sample. Stroke. 1997;28(3):766-770.
23. Cellucci T, Van Mater H, Graus F, et al. Clinical approach to the diagnosis of anti-NMDA receptor encephalitis: a single-center, longitudinal study of autoinflammatory diseases. Neurol Sci. 2012;17:604-607.
24. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771-1782.
25. Mina R, von Scheven E, Ardoipin SP, et al. Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2012;64(3):375-383.
26. Stirling C, Cardenale K, Van Mater H, et al. An update on the treatment of autoimmune encephalitis. Curr Treat Opt Rheumatol. 2018;4(1):14-28.
27. Graus F, Titulaer MJ, Balu R, et al. A clinical approach to diagnosis of autoimmune encephalitis in the pediatric patient. Neurol Neuroimmunol Neuroinflamm. 2020;7(2):e663.
28. Al-Diwani A, Handel A, Townsend L, et al. The psychopathology of NMDAR antibody encephalitis in adults: a systematic review and phenotypic analysis of individual patient data. Lancet Psychiatry. 2019;6(3):235-246.
29. Varley JA, Webb AJ, Balant B, et al. The Movement disorder associated with NMDAR antibody encephalitis is complex and characteristic: an expert video-rating study. J Neurol Neurosurg Psychiatry. 2019;90(6):724-726.
30. Suppäj E, Nosadini M, Zuliani L, et al. Plasma exchange in pediatric anti-NMDAR encephalitis: a systematic review. Brain Dev. 2016;38(7):613-622.
31. Eyre M, Hacohen Y, Barton C, Hemingway C, Lim M. Therapeutic plasma exchange in paediatric neurology: a critical review and proposed treatment algorithm. Dev Med Child Neurol. 2018;60(8):765-779.
32. Eyre M, Hacohen Y, Lamb R, et al. Utility and safety of plasma exchange in paediatric autoimmune encephalopathies. Dev Med Child Neurol. 2019;61(5):540-546.
33. Dogan ME, Onurgeno M, Golontchev KS, Bons C, et al. Immunoabsorption therapy in autoimmune encephalitides. Neurology Neuroscience Neuroinflammation. 2016;3(2):e207.
34. Heine J, Ly LT, Lieder J, et al. Immunoabsorption plasma or plasma exchange in the treatment of autoimmune encephalitis: a pilot study. J Neurol. 2016;263(12):2395-2402.
35. Zhang M, Li W, Zhou S, et al. Clinical features, treatment, and outcomes among Chinese children with anti-methyl-D-aspartate receptor (anti-NMDAR) encephalitis. Front Neurol. 2019;10:596.
36. Xu X, Lu Q, Huang Y, et al. Anti-NMDAR encephalitis: a single-center, longitudinal study in China. Neurol Neuroimmunol Neuroinflamm. 2019;7(1):e633.
37. Mo Y, Wang L, Zhu L, et al. Analysis of risk factors for a poor prognosis in patients with anti-N-methyl-D-aspartate receptor encephalitis and construction of a prognostic composite score. J Clin Neurol. 2020;16(3):438-447.
38. Raha S, Gadgil P, Sandhila C, Udani V. Nonparaneoplastic anti-N-methyl-D-aspartate receptor encephalitis: a case series of four children. Pediatr Neurol. 2012;46(4):246-249.
39. Nagappa M, Bindu PS, Mahadevan A, Sinha S, Mathuranath PS, Taly AB. Clinical features, therapeutic response, and follow-up in pediatric anti-N-methyl-D-aspartate receptor encephalitis: experience from a tertiary care university hospital in India. Neuropediatrics. 2016;47(1):24-32.
40. Nair AV, Menon J, Kuzhikkathukandiyil P. Clinical profile and neuropsychiatric outcome in children with anti-NMDAR encephalitis. Indian Pediatr. 2019;56(3):247-249.
41. Jones HF, Mohammad SS, Reed PW, et al. Anti-N-methyl-d-aspartate receptor encephalitis in Māori and Pacific Island children in New Zealand. Dev Med Child Neurol. 2017;59(7):719-724.
42. Lee WJ, Lee ST, Shin YW, et al. Teratoma removal, steroid, IVIG, rituximab and tocilizumab (T-SIRT) in anti-NMDAR encephalitis. Neurotherapeutics. 2017;14(1):487-487. doi: 10.1007/s13311-017-0522-0.
43. Sveinsson O, Granqvist M, Forslin Y, Blennow K, Zetterberg H, Piehl F. Successful combined targeting of B- and plasma cells in treatment refractory anti-NMDAR encephalitis. J Neuroimmunol. 2017;312:15-18.
44. Jun JS, Seo HG, Lee ST, Chu K, Lee SK. Botulinum toxin treatment for hypersalivation in anti-NMDA receptor encephalitis. Ann Clin Tradl Neurol. 2017;4(11):830-834.
45. Thomas A, Rauschloff P, Gresa-Arribas N, Schned A, Dalmau JO, Fadul CE. Anti-N-methyl-D-aspartate receptor antibody encephalitis: a patient with refractory illness after 25 months of intensive immunotherapy. JAMA Neurol. 2013;70(12):1566-1568.
46. DeSena AD, Greenberg BM, Graves D. Three phenotypes of anti-N-methyl-D-aspartate receptor antibody encephalitis in children: prevalence of symptoms and prognosis. Pediatr Neurol. 2014;51(4):542-549.
47. DeSena AD, Noland DK, Matevosyan K, et al. Intravenous methylprednisolone versus therapeutic plasma exchange for treatment of anti-N-methyl-D-aspartate receptor antibody encephalitis: a retrospective review. J Clin Apher. 2015;30(4):212-216.
48. Tateno K, Christen P, Rogemond V, Honnorat J, Tardieu M, Deiva K. Intrathecal treatment of anti-N-Methyl-D-aspartate receptor encephalitis in children. Dev Med Child Neurol. 2015;57(1):95-99.
49. Liba Z, Kayserova J, Elisak M, et al. Anti-N-methyl-D-aspartate receptor encephalitis: the clinical course in light of the chemokine and cytokine levels in cerebrospinal fluid. J Neuroinflammation. 2016;13(1):55.
50. Behrendt V, Krogus C, Reinacher-Schick A, Gold R, Kläuser I. Bortezomib treatment for patients with anti-N-methyl-d-aspartate receptor encephalitis. JAMA Neurol. 2016;73(10):1251-1253.
51. Mehr SR, Neely RC, Wiley M, Kumar AB. Profound autonomic instability complicated by multiple episodes of cardiac asystole and refractory bradycardia in a patient with anti-NMDA encephalitis. Case Rep Neurol Med. 2016;2016:7967526.
52. Scheibe F, Prüss H, Mengel AM, et al. Bortezomib for treatment of therapy-refractory anti-NMDA receptor encephalitis. Neurology. 2017;88(4):366-370.
53. Schroeder C, Back C, Kec U, et al. Breakthrough treatment with bortezomib for a patient with anti-NMDAR encephalitis. Clin Neurol Neurosurg. 2018;172:24-26.
54. Shin YW, Lee ST, Kim TJ, Jun JS, Chu K. Bortezomib treatment for severe refractory anti-NMDA receptor encephalitis. Ann Clin Tradl Neurol. 2018;5(5):598-605.
55. Keddie S, Crisp SJ, Blackaby J, et al. Plasma cell depletion with bortezomib in the treatment of refractory NMDAR-antibody encephalitis. Rational developments in immunological treatment. Eur J Neurol. 2018;25(11):1384-1388.
56. Jaanmohamed M, Knezevic W, Needham M, Salmon S. Primary lateral sclerosis-like picture in a patient with a remote history of anti-N-methyl-D-aspartate receptor (anti-NMDAR) antibody encephalitis. BMJ Case Rep. 2018;2018:bcr2017224060.
57. Yang XZ, Zhu HD, Ren HT, et al. Utility and safety of intrathecal methotrexate treatment in severe anti-N-methyl-D-aspartate receptor encephalitis: a pilot study. Chin Med J (Engl). 2018;131(2):156-160.
58. Dale RC, Bitot F, Fagan E, Earl J. Cerebrospinal fluid neopterin in paediatric neurology: a marker of active central nervous system inflammation. Dev Med Child Neurol. 2009;51(4):317-323.
59. Prechette ES, Zhou L, Galetta SL, Chen L, Dalmau J. Prolonged follow-up and CSF antibody titers in a patient with anti-NMDA receptor encephalitis. Neurology. 2011;76(7 suppl):S64-S66.
60. Gresa-Arribas N, Titulaer MJ, Torrents A, et al. Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis. JAMA Neurol. 2018;75(1):95-99.
International Consensus Recommendations for the Treatment of Pediatric NMDAR Antibody Encephalitis
Margherita Nosadini, Terrence Thomas, Michael Eyre, et al.
Neurol Neuroimmunol Neuroinflamm 2021;8;
DOI 10.1212/NXI.0000000000001052

This information is current as of July 22, 2021

Updated Information & Services
including high resolution figures, can be found at:
http://nn.neurology.org/content/8/5/e1052.full.html

References
This article cites 59 articles, 9 of which you can access for free at:
http://nn.neurology.org/content/8/5/e1052.full.html##ref-list-1

Permissions & Licensing
Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
http://nn.neurology.org/misc/about.xhtml#permissions

Reprints
Information about ordering reprints can be found online:
http://nn.neurology.org/misc/addir.xhtml#reprintsus